Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

Phase 1/2 Completed 31 enrolled HI-Bio, A Biogen Company

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is an open-label, multicentre study to characterize the safety and efficacy of the human anti-CD38 antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory)

Timeline

Start: 2019-10-15
Primary completion: 2022-01-19
Completion: 2022-08-02

Publications

Ahmad SB, Jefferson JA. Targeting B Cells and Plasma Cells in Glomerular Disease. J Am Soc Nephrol. 2025 Jun 4;36(9):1844-1857. doi: 10.1681/ASN.0000000772.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Felzartamab	Monoclonal antibody	—	Intravenous

Trial to Assess Safety and Efficacy of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN)

Summary

Timeline

Publications

Drugs

Indications